Yongtai Biotechnology-B (06978.HK) held a board of directors meeting on August 23 to consider and approve the mid-term performance.
On August 13th, GeLingHui announced that Yongtai Biology-B (06978.HK) plans to hold a board of directors meeting on August 23, 2024 (Friday) to consider and approve the mid-term performance of the company and its subsidiaries for the six months ending June 30, 2024, including its publication.
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Immunotech Biopharm CFO Steps Down
Yongtai Biological announced that Chen Ran has been appointed as Joint Company Secretary.
Yongtai Biology-B (06978) announced that Yang Ning has resigned as the Chief Financial Officer and Company Secretary due to his other business responsibilities and will no longer serve as the authorized representative of the company in accordance with Rule 3.05 of the Securities Listing Rules of the Hong Kong Stock Exchange, effective from July 26, 2024. Chen Ran and Leung Yui Ping have been appointed as the Joint Company Secretaries of the company; and Chen Ran has been appointed as the authorized representative, effective from July 26, 2024.
Yongtai Biotechnology-B (06978.HK): Yang Ning resigns as CFO.
On July 26th, Gelunhui announced that Mr. Yang Ning resigned as the company's CFO and company secretary due to his other business responsibilities, and in accordance with Rule 3.05 of the Securities Listing Rules of the Hong Kong Stock Exchange, he will no longer serve as the authorized representative of the company, which will take effect on July 26, 2024. The board of directors is pleased to announce that (i) Mr. Chen Ran and Ms. Liang Ruibing have been appointed as joint company secretaries of the company; and (ii) Mr. Chen has been appointed as an authorized representative, which will take effect on July 26, 2024.
Express News | Immunotech Biopharm Ltd - Yang Ning Resigned as CFO
Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit
Express News | Immunotech Biopharm - Disposed Total RMB80.0 Mln of Certificates of Deposits for RMB82.6 Mln
Yongtai Biology-B (06978.HK) sells a total of 80 million yuan worth of certificates of deposit.
On June 20th, Guronghui announced that, on July 20th, 2023, March 20th, 2024, and June 20th, 2024, the Group (through its indirectly wholly owned subsidiary, Beijing Yongtai) sold a total of RMB 80.0 million worth of certificates of deposit on the market for a total cost of approximately RMB 82.6 million through Minsheng Bank. The certificates of deposit generated a total unaudited interest income of approximately RMB 2.6 million.
HK stocks surge | Yongtai Biology-B(06978) hit a maximum increase of over 28%, the company delves into the field of cellular immunotherapy, accelerating EAL's efforts to expand indications research.
Yongtai Biology-B (06978) rose by up to 28%, as of press time, up 22.14%, at HKD 3.42 with a turnover of 5.4982 million Hong Kong dollars.
IMMUNOTECH-B: 2023 ANNUAL REPORT
Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023
Yongtai Bio-B (06978.HK)'s annual loss increased to 335 million yuan
Gelonghui, March 28, 丨 Yongtai Bio-B (06978.HK) announced that for the year ended December 31, 2023, the company's other revenue increased by about RMB 1.4 million or about 15.4% from about RMB 9.1 million in the previous year to about RMB 10.5 million. R&D expenditure increased by approximately RMB 1.1 million, or approximately 0.6%, from approximately RMB 176.2 million in the previous year to approximately RMB 177.3 million in the same year. Total loss and overall expenses during the year increased by approximately RMB321.1 million for the year ended 31 December 2022 by approximately RMB14
Yongtai Bio-B (06978) Announces 2023 Annual Results with R&D Expenses of 177 Million Yuan to Accelerate Research on Expanded Indications for EAL
Yongtai Bio-B (06978) disclosed the 2023 annual results announcement. The company achieved about 1 other revenue during the reporting period...
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED 31 DECEMBER 2023
Yongtai Bio-B (06978.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 18 | Yongtai Bio-B (06978.HK) announced that the company plans to hold a board meeting on March 28, 2024 (Thursday) to consider and approve (including) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
IMMUNOTECH-B: DATE OF BOARD MEETING
Changes in Hong Kong stocks | Yongtai Bio-B (06978) rose more than 8%. The company recently joined hands with Corning to expand product commercialization cooperation
The Zhitong Finance App learned that Yongtai Bio-B (06978) rose more than 8%. As of press release, it had risen 8.41% to HK$3.61. According to news, Yongtai Biotech and Corning signed a memorandum of business cooperation in Beijing on March 1. According to reports, with the signing of the Memorandum of Business Cooperation, the two sides will carry out deeper cooperation in the development and marketing of customized products, testing laboratories, new products, etc., to promote the commercialization and implementation of Yongtai's important R&D pipelines. A previous research report by Societe Generale Securities pointed out that cellular immunotherapy has grown rapidly in recent years and has shown great potential. The company is deeply involved in cellular immunotherapy
Yongtai Bio-B (06978) joins hands with Corning to expand product commercialization cooperation
This time, a memorandum of business cooperation was signed to prepare the two sides to expand commercialization of Yongtai products.
Immunotech Biopharm Obtains Clinical Trial Nod in China for Leukemia Drug
No Data